Cargando…
The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited. Methods: Ninety-four patients who received pyrotinib as a th...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428978/ https://www.ncbi.nlm.nih.gov/pubmed/34512325 http://dx.doi.org/10.3389/fphar.2021.682568 |
_version_ | 1783750476323356672 |
---|---|
author | Ouyang, D. J Chen, Q. T Anwar, M. Xie, N. Ouyang, Q. C. Fan, P. Z. Qian, L. Y. Chen, G. N. Zhou, E. X. Guo, L. Gu, X. W. Ding, B. N. Yang, X. H. Liu, L. P. Deng, C. Xiao, Z. Li, J. Wang, Y. Q. Zeng, S. Wang, Shouman Yi, Wenjun |
author_facet | Ouyang, D. J Chen, Q. T Anwar, M. Xie, N. Ouyang, Q. C. Fan, P. Z. Qian, L. Y. Chen, G. N. Zhou, E. X. Guo, L. Gu, X. W. Ding, B. N. Yang, X. H. Liu, L. P. Deng, C. Xiao, Z. Li, J. Wang, Y. Q. Zeng, S. Wang, Shouman Yi, Wenjun |
author_sort | Ouyang, D. J |
collection | PubMed |
description | Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited. Methods: Ninety-four patients who received pyrotinib as a third- or higher-line treatment for HER2-positive MBC were included in this retrospective study. The primary and secondary endpoints were overall survival (OS) and progression‐free survival (PFS). Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analysis were implemented to balance important patient characteristics between groups. Results: Thirty (31.9%) patients were pretreated with lapatinib and subsequently received pyrotinib as an anti-HER2 treatment, and 64 (68.1%) patients did not receive this treatment. The OS and PFS indicated a beneficial trend in lapatinib-naive group compared to lapatinib-treated group in either the original cohort (PFS: 9.02 vs 6.36 months, p = 0.05; OS: 20.73 vs 14.35 months, p = 0.08) or the PSM (PFS: 9.02 vs 6.08 months, p = 0.07; OS: 19.07 vs 18.00 months, p = 0.61) or IPTW (PFS: 9.90 vs 6.17 months, p = 0.05; OS: 19.53 vs 15.10 months, p = 0.08) cohorts. Subgroup analyses demonstrated lapatinib treatment-related differences in PFS in the premenopausal subgroup and the no prior trastuzumab treatment subgroup, but no significant differences were observed in OS. Conclusion: Pyrotinib-based therapy demonstrated promising effects in HER2-positive MBC patients in a real-world study, especially in lapatinib-naive patients, and also some activity in lapatinib-treated patients. |
format | Online Article Text |
id | pubmed-8428978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84289782021-09-10 The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study Ouyang, D. J Chen, Q. T Anwar, M. Xie, N. Ouyang, Q. C. Fan, P. Z. Qian, L. Y. Chen, G. N. Zhou, E. X. Guo, L. Gu, X. W. Ding, B. N. Yang, X. H. Liu, L. P. Deng, C. Xiao, Z. Li, J. Wang, Y. Q. Zeng, S. Wang, Shouman Yi, Wenjun Front Pharmacol Pharmacology Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited. Methods: Ninety-four patients who received pyrotinib as a third- or higher-line treatment for HER2-positive MBC were included in this retrospective study. The primary and secondary endpoints were overall survival (OS) and progression‐free survival (PFS). Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analysis were implemented to balance important patient characteristics between groups. Results: Thirty (31.9%) patients were pretreated with lapatinib and subsequently received pyrotinib as an anti-HER2 treatment, and 64 (68.1%) patients did not receive this treatment. The OS and PFS indicated a beneficial trend in lapatinib-naive group compared to lapatinib-treated group in either the original cohort (PFS: 9.02 vs 6.36 months, p = 0.05; OS: 20.73 vs 14.35 months, p = 0.08) or the PSM (PFS: 9.02 vs 6.08 months, p = 0.07; OS: 19.07 vs 18.00 months, p = 0.61) or IPTW (PFS: 9.90 vs 6.17 months, p = 0.05; OS: 19.53 vs 15.10 months, p = 0.08) cohorts. Subgroup analyses demonstrated lapatinib treatment-related differences in PFS in the premenopausal subgroup and the no prior trastuzumab treatment subgroup, but no significant differences were observed in OS. Conclusion: Pyrotinib-based therapy demonstrated promising effects in HER2-positive MBC patients in a real-world study, especially in lapatinib-naive patients, and also some activity in lapatinib-treated patients. Frontiers Media S.A. 2021-08-26 /pmc/articles/PMC8428978/ /pubmed/34512325 http://dx.doi.org/10.3389/fphar.2021.682568 Text en Copyright © 2021 Ouyang, Chen, Anwar, Xie, Ouyang, Fan, Qian, Chen, Zhou, Guo, Gu, Ding, Yang, Liu, Deng, Xiao, Li, Wang, Zeng, Wang and Yi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ouyang, D. J Chen, Q. T Anwar, M. Xie, N. Ouyang, Q. C. Fan, P. Z. Qian, L. Y. Chen, G. N. Zhou, E. X. Guo, L. Gu, X. W. Ding, B. N. Yang, X. H. Liu, L. P. Deng, C. Xiao, Z. Li, J. Wang, Y. Q. Zeng, S. Wang, Shouman Yi, Wenjun The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study |
title | The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study |
title_full | The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study |
title_fullStr | The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study |
title_full_unstemmed | The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study |
title_short | The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study |
title_sort | efficacy of pyrotinib as a third- or higher-line treatment in her2-positive metastatic breast cancer patients exposed to lapatinib compared to lapatinib-naive patients: a real-world study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428978/ https://www.ncbi.nlm.nih.gov/pubmed/34512325 http://dx.doi.org/10.3389/fphar.2021.682568 |
work_keys_str_mv | AT ouyangdj theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT chenqt theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT anwarm theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT xien theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT ouyangqc theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT fanpz theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT qianly theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT chengn theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT zhouex theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT guol theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT guxw theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT dingbn theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT yangxh theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT liulp theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT dengc theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT xiaoz theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT lij theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT wangyq theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT zengs theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT wangshouman theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT yiwenjun theefficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT ouyangdj efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT chenqt efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT anwarm efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT xien efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT ouyangqc efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT fanpz efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT qianly efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT chengn efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT zhouex efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT guol efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT guxw efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT dingbn efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT yangxh efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT liulp efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT dengc efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT xiaoz efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT lij efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT wangyq efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT zengs efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT wangshouman efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy AT yiwenjun efficacyofpyrotinibasathirdorhigherlinetreatmentinher2positivemetastaticbreastcancerpatientsexposedtolapatinibcomparedtolapatinibnaivepatientsarealworldstudy |